---
title: "The biopharma sector has been quite surreal lately, with LABU and XBI starting to skid again. The ne"
description: "The biopharma sector has been quite surreal lately, with LABU and XBI starting to skid again. The news keeps pushing big industry deals every day, but then leading stock Moderna withdrew a filing, dir"
type: "topic"
locale: "en"
url: "https://longbridge.com/en/topics/38726353.md"
published_at: "2026-02-13T14:05:57.000Z"
author: "[瑞控股](https://longbridge.com/en/profiles/7200502)"
---

# The biopharma sector has been quite surreal lately, with LABU and XBI starting to skid again. The ne

The biopharma sector has been quite surreal lately, with LABU and XBI starting to skid again. The news keeps pushing big industry deals every day, but then leading stock Moderna withdrew a filing, directly cooling down sector sentiment. The volatility index of the triple-long LABU went off the charts. Sometimes I really feel that chasing these high-Beta ETFs is like riding a roller coaster; you might not get the red envelope, but getting dizzy is for real. Faith and drawdowns keep swinging back and forth, making me feel like an old naive investor, unsure whether to average down or just watch the show with a zen attitude.

### Related Stocks

- [LABU.US - Direxion S&P Biotech Bull 3X](https://longbridge.com/en/quote/LABU.US.md)
- [XBI.US - SPDR S&P Biotech](https://longbridge.com/en/quote/XBI.US.md)
- [MRNA.US - Moderna](https://longbridge.com/en/quote/MRNA.US.md)

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.